Natera Partners with Diakonos to Evaluate New Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Collaboration Background: Natera has partnered with Diakonos Oncology Corp. to utilize Signatera™ for assessing molecular responses in patients with refractory melanoma enrolled in the DOC-RM clinical trial, marking a significant advancement in precision medicine for cancer treatment.
- Clinical Trial Progress: The DOC-RM trial, which began enrollment in May, evaluates the FDA Fast Track-designated DOC1021 therapy, aiming to provide new treatment options for patients with unresectable or metastatic cutaneous melanoma, indicating potential positive impacts on patient outcomes.
- Technical Advantage: By analyzing circulating tumor DNA (ctDNA) at multiple timepoints, Natera's Signatera test can offer earlier insights into molecular responses compared to traditional imaging, enabling physicians to better understand treatment dynamics and optimize therapeutic strategies.
- Market Demand: Patients with refractory melanoma face significant unmet medical needs, and the collaboration between Natera and Diakonos not only aims to address this gap but also has the potential to drive the development of new therapies, enhancing patient survival rates and quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 213.940
Low
205.00
Averages
262.92
High
300.00
Current: 213.940
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Natera Initiates SIGNAL-ER 101 Study for Early-Stage Breast Cancer
- Study Launch: Natera Inc. has enrolled its first patient in the SIGNAL-ER 101 study, aimed at facilitating diagnosis and treatment for early-stage breast cancer through the Signatera MRD test, marking a significant advancement in precision medicine.
- Patient Recruitment Plan: The study plans to enroll 725 intermediate-risk HR+/HER- early-stage breast cancer patients, allowing those diagnosed as MRD negative via the Signatera test to receive endocrine therapy alone, thus avoiding unnecessary CDK4/6 inhibitor treatment.
- Efficacy Improvement: Endocrine therapy shows a 95% recurrence-free success rate in MRD negative patients, highlighting the importance of the Signatera test in optimizing treatment regimens and potentially improving patient outcomes significantly.
- Market Reaction: Natera's stock is currently trading at $205.52, up 1.19%, reflecting positive market sentiment regarding the progress of its new study, which may drive further investment and development in the precision medicine sector.
See More
Natera Partners with Diakonos to Evaluate New Therapy
- Collaboration Background: Natera has partnered with Diakonos Oncology Corp. to utilize Signatera™ for assessing molecular responses in patients with refractory melanoma enrolled in the DOC-RM clinical trial, marking a significant advancement in precision medicine for cancer treatment.
- Clinical Trial Progress: The DOC-RM trial, which began enrollment in May, evaluates the FDA Fast Track-designated DOC1021 therapy, aiming to provide new treatment options for patients with unresectable or metastatic cutaneous melanoma, indicating potential positive impacts on patient outcomes.
- Technical Advantage: By analyzing circulating tumor DNA (ctDNA) at multiple timepoints, Natera's Signatera test can offer earlier insights into molecular responses compared to traditional imaging, enabling physicians to better understand treatment dynamics and optimize therapeutic strategies.
- Market Demand: Patients with refractory melanoma face significant unmet medical needs, and the collaboration between Natera and Diakonos not only aims to address this gap but also has the potential to drive the development of new therapies, enhancing patient survival rates and quality of life.
See More
Natera Launches SIGNAL-ER 101 Trial for Breast Cancer Treatment De-escalation
- SIGNAL-ER 101 Trial Launch: Natera has initiated the SIGNAL-ER 101 trial to evaluate the clinical utility of Signatera MRD-guided de-escalation strategies in early-stage HR+/HER2- breast cancer, aiming to enroll 725 patients across 50 sites in the U.S.
- Standard of Care Transformation: The current standard recommends 2-3 years of CDK4/6 inhibitors for intermediate-risk HR+/HER2- breast cancer patients, yet only about 3% benefit, with over 60% experiencing serious adverse events, indicating a critical need to reassess treatment necessity and efficacy.
- Potential of MRD-Negative Patients: Data shows that MRD-negative patients tested with Signatera have over 95% distant recurrence-free interval at 5 years, suggesting they can safely defer CDK4/6 inhibition, thereby reducing unnecessary treatments and associated side effects.
- Optimizing Treatment Strategies: The implementation of SIGNAL-ER 101 not only helps mitigate overtreatment in breast cancer patients but also provides crucial evidence for Natera's innovations in cancer treatment, supporting MRD-based personalized treatment optimization and enhancing patient quality of life.
See More
FDA Approves Tecentriq for Bladder Cancer Treatment
- New Indication Approved: The FDA has approved Roche-owned Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), specifically targeting those with circulating tumor DNA molecular residual disease after cystectomy, marking a significant expansion in cancer treatment applications.
- Companion Diagnostic Approved: The FDA also approved Natera's Signatera CDx as a companion diagnostic for this indication, aimed at identifying ctDNA MRD-positive patients who are likely to benefit from Tecentriq therapy, thereby enhancing treatment precision and effectiveness.
- Increased Indications: Tecentriq now boasts 11 approved indications, demonstrating its broad applicability in oncology and strengthening Roche's competitive position in the oncology market while providing patients with more treatment options.
- Positive Market Outlook: With the expansion of Tecentriq's indications, Roche's market outlook in oncology appears optimistic, expected to drive future sales growth and solidify its leadership position in the biopharmaceutical industry.
See More
Natera Receives FDA Approval for Personalized MRD Testing
- FDA Approval Milestone: Natera's Signatera CDx has received FDA approval as the first personalized molecular residual disease (MRD) test for MIBC patients, marking a new standard in precision cancer treatment that is expected to significantly improve outcomes for MRD-positive patients.
- Clinical Trial Support: The IMvigor011 trial demonstrated that MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival (DFS) and overall survival (OS), while MRD-negative patients had a 97% two-year OS without any adjuvant therapy, providing crucial evidence for clinical decision-making.
- Significant Market Potential: With approximately 30,000 new MIBC diagnoses annually in the U.S. and 150,000 globally, the application of Signatera will assist physicians in accurately identifying recurrence risks, optimizing treatment plans, and reducing unnecessary therapies, thereby enhancing patient quality of life.
- Signal of Industry Transformation: This approval not only validates Natera's decade-long vision but also propels the advancement of precision oncology, likely leading to the application of MRD testing across more cancer types, further improving patient treatment outcomes and survival rates.
See More
Natera Reports Q1 Results Exceeding Revenue Expectations with 38.8% Growth
- Significant Revenue Growth: Natera's Q1 revenue reached $696.6 million, reflecting a 38.8% year-over-year increase that surpassed analyst expectations of $613.9 million, indicating strong market demand in women's health and oncology sectors.
- GAAP Loss Exceeds Expectations: Despite robust revenue, Natera reported a GAAP loss of $0.60 per share, which was worse than the anticipated $0.55 loss, leading to a negative market reaction that impacted stock performance.
- Surge in Clinical Testing Demand: Clinical oncology testing volumes grew by 55% year-over-year, driven by strong demand for the Signatera product and increased physician adoption, highlighting the company's competitive position in the cancer detection market.
- Future Growth Potential: Natera plans to launch Signatera in Japan, which is expected to significantly expand its colorectal cancer testing market, while also investing in early detection platforms to drive long-term growth opportunities.
See More
Natera Initiates SIGNAL-ER 101 Study for Early-Stage Breast Cancer
- Study Launch: Natera Inc. has enrolled its first patient in the SIGNAL-ER 101 study, aimed at facilitating diagnosis and treatment for early-stage breast cancer through the Signatera MRD test, marking a significant advancement in precision medicine.
- Patient Recruitment Plan: The study plans to enroll 725 intermediate-risk HR+/HER- early-stage breast cancer patients, allowing those diagnosed as MRD negative via the Signatera test to receive endocrine therapy alone, thus avoiding unnecessary CDK4/6 inhibitor treatment.
- Efficacy Improvement: Endocrine therapy shows a 95% recurrence-free success rate in MRD negative patients, highlighting the importance of the Signatera test in optimizing treatment regimens and potentially improving patient outcomes significantly.
- Market Reaction: Natera's stock is currently trading at $205.52, up 1.19%, reflecting positive market sentiment regarding the progress of its new study, which may drive further investment and development in the precision medicine sector.
See More
Natera Partners with Diakonos to Evaluate New Therapy
- Collaboration Background: Natera has partnered with Diakonos Oncology Corp. to utilize Signatera™ for assessing molecular responses in patients with refractory melanoma enrolled in the DOC-RM clinical trial, marking a significant advancement in precision medicine for cancer treatment.
- Clinical Trial Progress: The DOC-RM trial, which began enrollment in May, evaluates the FDA Fast Track-designated DOC1021 therapy, aiming to provide new treatment options for patients with unresectable or metastatic cutaneous melanoma, indicating potential positive impacts on patient outcomes.
- Technical Advantage: By analyzing circulating tumor DNA (ctDNA) at multiple timepoints, Natera's Signatera test can offer earlier insights into molecular responses compared to traditional imaging, enabling physicians to better understand treatment dynamics and optimize therapeutic strategies.
- Market Demand: Patients with refractory melanoma face significant unmet medical needs, and the collaboration between Natera and Diakonos not only aims to address this gap but also has the potential to drive the development of new therapies, enhancing patient survival rates and quality of life.
See More
Natera Launches SIGNAL-ER 101 Trial for Breast Cancer Treatment De-escalation
- SIGNAL-ER 101 Trial Launch: Natera has initiated the SIGNAL-ER 101 trial to evaluate the clinical utility of Signatera MRD-guided de-escalation strategies in early-stage HR+/HER2- breast cancer, aiming to enroll 725 patients across 50 sites in the U.S.
- Standard of Care Transformation: The current standard recommends 2-3 years of CDK4/6 inhibitors for intermediate-risk HR+/HER2- breast cancer patients, yet only about 3% benefit, with over 60% experiencing serious adverse events, indicating a critical need to reassess treatment necessity and efficacy.
- Potential of MRD-Negative Patients: Data shows that MRD-negative patients tested with Signatera have over 95% distant recurrence-free interval at 5 years, suggesting they can safely defer CDK4/6 inhibition, thereby reducing unnecessary treatments and associated side effects.
- Optimizing Treatment Strategies: The implementation of SIGNAL-ER 101 not only helps mitigate overtreatment in breast cancer patients but also provides crucial evidence for Natera's innovations in cancer treatment, supporting MRD-based personalized treatment optimization and enhancing patient quality of life.
See More
FDA Approves Tecentriq for Bladder Cancer Treatment
- New Indication Approved: The FDA has approved Roche-owned Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), specifically targeting those with circulating tumor DNA molecular residual disease after cystectomy, marking a significant expansion in cancer treatment applications.
- Companion Diagnostic Approved: The FDA also approved Natera's Signatera CDx as a companion diagnostic for this indication, aimed at identifying ctDNA MRD-positive patients who are likely to benefit from Tecentriq therapy, thereby enhancing treatment precision and effectiveness.
- Increased Indications: Tecentriq now boasts 11 approved indications, demonstrating its broad applicability in oncology and strengthening Roche's competitive position in the oncology market while providing patients with more treatment options.
- Positive Market Outlook: With the expansion of Tecentriq's indications, Roche's market outlook in oncology appears optimistic, expected to drive future sales growth and solidify its leadership position in the biopharmaceutical industry.
See More
Natera Receives FDA Approval for Personalized MRD Testing
- FDA Approval Milestone: Natera's Signatera CDx has received FDA approval as the first personalized molecular residual disease (MRD) test for MIBC patients, marking a new standard in precision cancer treatment that is expected to significantly improve outcomes for MRD-positive patients.
- Clinical Trial Support: The IMvigor011 trial demonstrated that MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival (DFS) and overall survival (OS), while MRD-negative patients had a 97% two-year OS without any adjuvant therapy, providing crucial evidence for clinical decision-making.
- Significant Market Potential: With approximately 30,000 new MIBC diagnoses annually in the U.S. and 150,000 globally, the application of Signatera will assist physicians in accurately identifying recurrence risks, optimizing treatment plans, and reducing unnecessary therapies, thereby enhancing patient quality of life.
- Signal of Industry Transformation: This approval not only validates Natera's decade-long vision but also propels the advancement of precision oncology, likely leading to the application of MRD testing across more cancer types, further improving patient treatment outcomes and survival rates.
See More
Natera Reports Q1 Results Exceeding Revenue Expectations with 38.8% Growth
- Significant Revenue Growth: Natera's Q1 revenue reached $696.6 million, reflecting a 38.8% year-over-year increase that surpassed analyst expectations of $613.9 million, indicating strong market demand in women's health and oncology sectors.
- GAAP Loss Exceeds Expectations: Despite robust revenue, Natera reported a GAAP loss of $0.60 per share, which was worse than the anticipated $0.55 loss, leading to a negative market reaction that impacted stock performance.
- Surge in Clinical Testing Demand: Clinical oncology testing volumes grew by 55% year-over-year, driven by strong demand for the Signatera product and increased physician adoption, highlighting the company's competitive position in the cancer detection market.
- Future Growth Potential: Natera plans to launch Signatera in Japan, which is expected to significantly expand its colorectal cancer testing market, while also investing in early detection platforms to drive long-term growth opportunities.
See More
